TONSL

Across TCGA pan-cancer cohorts, TONSL mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TONSL data layer compared with 29 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TONSL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TONSL expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where TONSL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.919	0.592	.001	27	view →
COAD	DFS	Median	All	0.807	1.000	.042	24	view →
HNSC	OS	Median	All	0.795	0.904	.005	23	view →
LUAD	OS	Median	All	0.594	0.821	.017	7	view →
PDAC	DFS	Quartile	All	0.280	0.476	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TONSL–CCRCC (DFS)

Open the CCRCC breakdown →